| Display title | Chemistry:Fevipiprant |
| Default sort key | Fevipiprant |
| Page length (in bytes) | 4,531 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 814781 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Jport |
| Date of page creation | 00:39, 6 February 2024 |
| Latest editor | imported>Jport |
| Date of latest edit | 00:39, 6 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Fevipiprant (INN; code name QAW039) is a drug of the piprant class that was being developed by Novartis. It is a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2 or CRTh2).
By 2016 it had advanced to phase III clinical trials for the treatment of asthma. However, in 2019... |
